Volume 19 Issue 3 September 2010Original Research
Observational study comparing intranasal mometasone
furoate with oral antihistamines for rhinitis and asthma
Pages 266-273
*David Pricea,b, Linda Kempb, Erika Simsb, Julie von Ziegenweidtb, Prakash Navaratnamc, Amanda J Leed, Alison Chisholmb, Elizabeth V Hillyerb, Gokul Gopalane
a
Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK
b
Research in Real Life Ltd, Norwich, UK
c
Global Outcomes Research, Merck & Co., Inc., Whitehouse Station, NJ, USA.
d
Medical Statistics Team, Section of Population Health, University of Aberdeen, Aberdeen, UK
e
Global Medical Affairs Department, Merck & Co., Inc., Whitehouse Station, NJ, US
Received 16 February 2010 • Accepted 17 May 2010 • Online 22 June 2010
Abstract
AIMS: Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma
receiving mometasone furoate – an intranasal corticosteroid with low systemic bioavailability – or an oral antihistamine.
METHODS: 395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio
to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy
measures.
RESULTS: Asthma control was achieved by 309/395 (78.2%) versus 580/790 (73.4%; p=0.071) patients in the mometasone and
antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2%) versus 539 (68.2%; p=0.035), respectively. The adjusted
odds ratios for antihistamines, relative to mometasone, were 0.71 (95% CI, 0.52–0.98) for achieving asthma control and 0.74 (95% CI,
0.56–0.97) for achieving rhinitis control.
CONCLUSIONS: Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower
airway outcomes with intranasal mometasone than with oral antihistamine.
Keywords
Antihistamine, asthma, control, mometasone furoate, one airway, rhinitis
* Corresponding author. David Price Tel: +44 1224 554588 Fax: +44 1224 550683 Email: david@respiratoryresearch.org | |
|
